Highlights
- Potential investors are searching for Grail IPO, and the biotechnology company’s name surface on trending charts in the US.
- Grail is working on early detection of cancer as it believes that it is important to improve treatment of the deadly disease.
- The biopharmaceutical company has developed a test named Galleri that is capable of detecting 50 types of cancer.
Retail investors in North American markets are looking up for Grail stock as the company's name surfaced on the trending charts in the US.
Grail is a California-based biotechnology and pharmaceutical company, and it develops products for the early detection of cancer. Using innovative technologies, data science, and next-generation sequencing (NGS) to address serious health issues by developing efficient products.
Grail is working on early detection of cancer as it believes that it is important to improve treatment of the deadly disease. According to the company website, 71 per cent of cancer deaths are caused by cancers that are not screened commonly.
The biopharmaceutical company has developed a test named Galleri that is capable of detecting 50 types of cancer. The product is designed in such a manner that only a blood sample can be used for the early detection of cancer.
Can you buy Grail stock?
In September 2020, Grail announced that it had filed for an initial public offering (IPO) with the US Securities and Exchange Commission.

© 2021 Kalkine Media®
The biotechnology company had applied to list its shares on the Nasdaq and trade under the stock symbol GRAL. However, Grail withdrew its IPO plans after Illumina Inc. (NASDAQ:ILMN) acquired it.
Illumina completed the acquisition of Grail in August 2021 and the US Federal Trade Commission challenged the acquisition.
Also Read: Samsara IPO: How to buy the IoT software company's stock?
As Grail did not become a publicly-traded company, interested investors cannot invest their money in this stock. However, there's an alternate option of investing in Illumina as it trades on the Nasdaq and its last closing price was US$ 391.74 per share.
Bottom line
There’s no announcement from Illumina about Grail’s IPO plans. Although the acquisition is completed, it is uncertain if Illumina will make Grail a publicly-traded company.
Illumina recorded a revenue of US$ 1,108 million in Q3 2021, representing an increase of 40 per cent year-over-year (YoY).
Meanwhile, the GAAP net income of the healthcare company was US$ 317 million in the third quarter of this year.
Also Read: Reddit IPO: How to buy this discussion forum's stock?